We are live on ! Find out more

Heart Test Laboratories

HSCS

Market cap $20.8M

4.30 USD

+0.41

10.54%

At close Updated Oct 2, 4:00 PM EDT

1 day

10.54%

5 days

-7.53%

1 month

42.86%

3 months

54.12%

6 months

86.96%

Year to date

36.94%

1 year

16.53%

5 years

-97.47%

10 years

-97.47%

About: HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare setting, either via the MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via the MyoVista wavECG Device.

Employees: 14

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 83.3%

Negative 16.7%

Fortitude Appoints Kimberly Pittman as Chief Legal Officer

FAIRPORT, N.Y.--(BUSINESS WIRE)--Fortitude Mining Holdings, Inc. (“Fortitude” or the “Company”), a vertically-integrated digital asset mining platform anchored in Zcash, today announced the appointment of Kimberly Pittman as Chief Legal Officer, effective September 28. Pittman joins Fortitude's executive leadership team as the Company prepares for its previously announced proposed business combination with HeartSciences Inc. (Nasdaq: HSCS) (“HeartSciences”). In her role, Pittman will work along.

Fortitude Appoints Kimberly Pittman as Chief Legal Officer

HeartSciences Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update

Proposed business combination with Fortitude, a vertically-integrated digital asset mining platform anchored in Zcash, continues to progress, with closing expected in Q4 calendar 2026

HeartSciences Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update

Zacks Investment Research

HeartSciences Inc. (HSCS) Reports Q1 Loss, Misses Revenue Estimates

HeartSciences Inc. (HSCS) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to a loss of $1.58 per share a year ago.

HeartSciences Inc. (HSCS) Reports Q1 Loss, Misses Revenue Estimates

Fortitude Invests $1.0 Million in HeartSciences at a 22% Premium with No Adjustment to the Merger Consideration

Fortitude purchased approximately $1,000,000 of HeartSciences' shares of common stock at $2.43 per share, a 22% premium to the closing price on the purchase date The exchange ratio under the merger agreement with Fortitude is unchanged, and no additional shares will be issued to holders of Fortitude's equity interests at closing as a result of the investment Following the investment, Fortitude holds approximately 9.4% of HeartSciences' outstanding shares of common stock Southlake, TX, Aug. 19, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today announced that on August 12, 2026 Fortitude Mining Holdings, Inc. (“Fortitude”) purchased 411,522 shares of HeartSciences' common stock for an aggregate purchase price of approximately $1,000,000 in a private placement (the “Investment”). The shares were issued at a negotiated price of $2.43 per share, representing a 22% premium to the closing price of HeartSciences' common stock on the purchase date.

Fortitude Invests $1.0 Million in HeartSciences at a 22% Premium with No Adjustment to the Merger Consideration

HeartSciences Files Preliminary Proxy Statement for Business Combination with Fortitude Mining Holdings; Provides Business Update and Reports Fiscal 2026 Financial Results

Company believes proposed Fortitude Mining Holdings business combination represents a significant value creation opportunity for the Company's shareholders Fiscal 2026 saw the full commercial launch of the MyoVista Insights platform and submission of the MyoVista wavECG device to the FDA for 510(k) clearance

HeartSciences Files Preliminary Proxy Statement for Business Combination with Fortitude Mining Holdings; Provides Business Update and Reports Fiscal 2026 Financial Results

HeartSciences Files Its Fiscal 2026 Annual Report on Form 10-K

Company believes proposed Fortitude merger represents a significant opportunity for the Company's shareholders; preliminary proxy statement in connection with the Proposed Transaction expected to be filed shortly, with fiscal 2026 earnings release and business update to follow Company believes proposed Fortitude merger represents a significant opportunity for the Company's shareholders; preliminary proxy statement in connection with the Proposed Transaction expected to be filed shortly, with fiscal 2026 earnings release and business update to follow

HeartSciences Files Its Fiscal 2026 Annual Report on Form 10-K

Fortitude and HeartSciences (Nasdaq: HSCS) Announce Business Combination, Aiming to Bring a Leading Vertically-Integrated Zcash Mining Platform to the Public Markets

FAIRPORT, N.Y.--(BUSINESS WIRE)--Fortitude Mining Holdings, Inc. ("Fortitude"), a vertically-integrated digital asset mining platform anchored in Zcash, and HeartSciences Inc. (Nasdaq: HSCS) (“HeartSciences”), an AI-powered medical technology company, today announced that they have entered into a definitive merger agreement to combine in an all-stock transaction (the “Proposed Transaction”) which is expected to close in H2 2026. Upon closing, the combined company will operate under the Fortitud.

Fortitude and HeartSciences (Nasdaq: HSCS) Announce Business Combination, Aiming to Bring a Leading Vertically-Integrated Zcash Mining Platform to the Public Markets

European Patent Granted for ECG-Based Assessment of Diastolic Function, Expands HeartSciences' Patent Portfolio to More Than 45 Granted Patents

Patent covers machine-learning models that use ECG data to estimate echocardiogram parameters indicative of diastolic function Patent covers machine-learning models that use ECG data to estimate echocardiogram parameters indicative of diastolic function

European Patent Granted for ECG-Based Assessment of Diastolic Function, Expands HeartSciences' Patent Portfolio to More Than 45 Granted Patents

HeartSciences Launches MyoVista Insights™ Version 1.3 with AI-ECG Algorithm Marketplace and First FDA-Cleared Algorithm

Bunkerhill Health's FDA-cleared ECG-EF algorithm for the detection of reduced ejection fraction becomes the first cleared AI-ECG algorithm available through MyoVista Insights, advancing HeartSciences' SaaS-based, recurring-revenue marketplace strategy Bunkerhill Health's FDA-cleared ECG-EF algorithm for the detection of reduced ejection fraction becomes the first cleared AI-ECG algorithm available through MyoVista Insights, advancing HeartSciences' SaaS-based, recurring-revenue marketplace strategy

HeartSciences Launches MyoVista Insights™ Version 1.3 with AI-ECG Algorithm Marketplace and First FDA-Cleared Algorithm

HeartSciences Signs Commercial Agreement with North Shore Health, the First Hospital Deployment from the Cibolo Health Network

Agreement follows Cibolo Health's endorsement of MyoVista Insights for its network of 127 independent hospitals and reflects continued commercial momentum for HeartSciences' ECG management platform Agreement follows Cibolo Health's endorsement of MyoVista Insights for its network of 127 independent hospitals and reflects continued commercial momentum for HeartSciences' ECG management platform

HeartSciences Signs Commercial Agreement with North Shore Health, the First Hospital Deployment from the Cibolo Health Network

See News Rankings

Price charts implemented using Lightweight Charts™